phytomenadione
DrugBlood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.
NCT Number: NCT03782025
Critically ill patients with spontaneously prolonged pro-thrombin time, where administration of intravenous administration of phytomenadione (vitamin K) has been ordered by the treating physician will be identified. After signed informed consent baseline samples will be collected. Phytomenadione will be given and 24 hours after administration new blood samples will be collected. Several different advanced coagulation and vitamin K-assays will be performed before and 24 hours after vitamin K administration.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Intensive and perioperative care. Skåne University Hospital. Lund, Lund, Skåne County, Sweden
Vitamin K-deficiency is common in the peri-operative and intensive care setting. It is often seen in patients with prolonged prothrombin complex (PK-INR). A prolonged (PK-INR) is sometimes treated with intravenous vitamin K, even in non-warfarin treated or non-liver failure patients. Despite the development of this practice the knowledge about how intravenously given vitamin K affects routine coagulation status and other advanced laboratory coagulations assays is rare.
The aim of this study is to investigate the effects of intravenously administered vitamin K on routine coagulation status and on advanced coagulation and vitamin K-assays in post-operative- and critically ill patients with prolonged PK-INR.
Patients with spontaneously prolonged PK-INR are routinely given intravenous vitamin K but it is largely unknown how this procedure affects the included coagulation assays. This research project may contribute to increased knowledge concerning effects of intravenously given vitamin K in critical ill patients with spontaneous coagulopathies. Since spontaneous coagulopathy is frequently occurring in critically ill and postoperative patients due to various underlying conditions and current evidence for vitamin K administration is based on scarce evidence more research in this area is motivated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.
Time frame: Before and 24 hours after given phytomenadione
Prothrombin complex (PK-INR) with Owren and Quick reagents
Time frame: Before and 24 hours after given phytomenadione
Time frame: Before and 24 hours after given phytomenadione
Protein Induced by Vitamin K Absence or antagonism for factor II (PIVKA-II)
Time frame: Before and 24 hours after given phytomenadione
Time frame: Before and 24 hours after given phytomenadione
Dephospho-uncarboxylated Matrix Gla Protein (dp-ucMGP)
Time frame: Before and 24 hours after given phytomenadione
Time frame: Before and 24 hours after given phytomenadione
Thromboelastometry using ROTEM with tissue factor activation (EXTEM reagent)
Region Skane
Other
Effect of Vitamin K in Critically Ill Patients With Spontaneously Increased Pro-thrombin Time Measured With Routine Coagulation Tests and Advanced Coagulation- and Vitamin K-assays
Acronym: VITAKOAG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06727669
Arterial Thromboembolism, Autoimmune Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT03634215
Cardiovascular Diseases, Coagulation Defect; Acquired
Liberec, Liberec Region, Czechia
View Trial DetailsNCT03754868
Coagulation Factor Deficiency, Extracorporeal Membrane Oxygenation Complication
Göttingen, Germany
View Trial DetailsNCT06481995
Cardiovascular Diseases, Coagulation Disorder
Geneva, Canton of Geneva, Switzerland
View Trial Details